An overview on analytical estimation of ertugliflozin

https://doi.org/10.54037/WJPS.2021.91106

Abstract

Ertugliflozin is a medicine that is used to treat type 2 diabetes. It's given as a solo medication or in a fixed-dose combination with sitagliptin or metformin. Ertugliflozin belongs to the gliflozin class of medications and is a sodium/glucose cotransporter 2 (SGLT2) inhibitor. In the already available literature, various analytical and bioanalytical methods are feasible. The two aspects of the analytical methods covered here are spectroscopy and chromatography. Advanced analytical techniques such as 3D fluorescence spectroscopy, HPLC, HILIC, and UPLC MS/MS were used to examine Ertugliflozin in pure, dosage forms, and a variety of biological matrixes. This paper undoubtedly beneficial in future for the researchers who are working in development and validation of various analytical methods for quantification of Ertugliflozin form its bulk and pharmaceutical dosage form.